VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
XLO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
XLOXilio Therapeutics, Inc.
$7.54$50M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksXLOFinancials

Xilio Therapeutics, Inc. (XLO) Income Statement

7Y historyFree accessUpdated daily

Revenue has been lumpy, peaking at $19.1M in 2025Q3 and reaching $18.7M in 2026Q2, while operating margin remained negative at -18.7% and net margin at -34.1% in the latest quarter.

Income StatementBalance SheetCash FlowRatios

XLO Income Statement

Annual statement

XLO Income Statement

Xilio Therapeutics, Inc. (XLO) annual income statement — 7-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19
Sales/Revenue55.01M43.77M6.34M00000
Revenue Growth %72.97%589.88%------
Cost of Goods Sold344K1.54M0001.5M1.06M240K
COGS % of Revenue-3.52%------
Gross Profit54.67M42.23M6.34M00-1.5M-1.06M-240K
Gross Margin %99.37%96.48%100%-----
Gross Profit Growth %-565.59%--100%-40.75%-343.75%-
Operating Expenses95.85M84.21M66.93M79.13M89.15M73.55M53.5M18.79M
OpEx % of Revenue-192.4%1054.95%-----
Selling, General & Admin28.54M29.71M24.78M27M29.95M22.36M9.59M4.53M
SG&A % of Revenue-67.88%390.57%-----
Research & Development67.32M56.04M41.21M52.14M59.2M51.19M43.91M14.26M
R&D % of Revenue-128.04%649.61%-----
Other Operating Expenses0-1.54M937K00000
Operating Income-41.19M-41.98M-60.58M-79.13M-89.15M-75.04M-54.56M-19.03M
Operating Margin %-74.87%-95.92%-954.95%-----
Operating Income Growth %-30.7%23.44%11.24%-18.8%-37.54%-186.77%-
EBITDA-39.87M-40.44M-58.94M-77.23M-87.3M-73.55M-53.5M-18.79M
EBITDA Margin %-72.48%-92.4%-929.04%-----
EBITDA Growth %5.48%31.38%23.69%11.53%-18.71%-37.47%-184.76%-
D&A (Non-Cash Add-back)1.32M1.54M1.64M1.9M1.85M1.5M1.06M240K
EBIT-11.49M-35.04M-59.65M-76.4M-88.22M-75.2M-54.62M-17.31M
Net Interest Income03.4M-100K00-599.4K-599.4K0
Interest Income03.4M0006006000
Interest Expense00100K00600K600K0
Other Income/Expense29.7M6.95M2.34M2.73M927K-756K-656K1.72M
Pretax Income-11.49M-35.04M-58.24M-76.4M-88.22M-75.8M-55.22M-17.31M
Pretax Margin %-20.89%-80.05%-918.05%-----
Income Tax00000000
Effective Tax Rate %0%0%0%0%0%0%0%0%
Net Income-11.49M-35.04M-58.24M-76.4M-88.22M-75.8M-55.22M-17.31M
Net Margin %-20.89%-80.05%-918.05%-----
Net Income Growth %80.36%39.84%23.77%13.4%-16.39%-37.27%-218.98%-
Net Income (Continuing)-11.49M-35.04M-58.24M-76.4M-88.22M-75.8M-55.22M-17.31M
Discontinued Operations00000000
Minority Interest00000000
EPS (Diluted)-0.58-4.19-15.26-38.92-45.08-189.28-1475.88-592.06
EPS Growth %96.43%72.54%60.79%13.66%76.18%87.18%-149.28%-
EPS (Basic)--4.19-15.26-38.92-45.08-189.28-1475.88-592.06
Diluted Shares Outstanding19.69M8.36M3.82M1.96M1.96M400.45K37.41K29.24K
Basic Shares Outstanding19.69M8.36M3.82M1.96M1.96M400.45K37.41K29.24K
Dividend Payout Ratio--------

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetMixed
Cash FlowMixed
Top Statement Risk

Revenue volatility and persistent operating losses

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Lumpy Collaboration Revenue Drives Growth

Based on the reported quarterly income statements, XLO's revenue swung from $2.9M in 2025Q1 to $19.1M in 2025Q3 before falling to $12.6M in 2026Q1, a pattern that points to milestone or collaboration recognition rather than a steady commercial base.

The 131.2% sequential jump to $18.7M in 2026Q2 following a 3.3% gain in the prior quarter suggests revenue is being recognized in discrete tranches rather than accruing from recurring sales. Because no product revenue is visible in the supplied data, investors should monitor whether these inflows reflect durable partnership economics or one-time recognition events. The absence of a consistent trend makes growth durability difficult to assess from reported figures alone.

Operating Losses Persist Despite Revenue Gains

As reported in the income statements, XLO's operating loss narrowed to -$3.5M in 2026Q2 from -$14.1M in 2026Q1, yet R&D spend of $14.6M and SG&A of $7.6M still exceeded the $18.7M revenue base, leaving operating margin at -18.7%.

The improvement in operating income appears driven primarily by the revenue spike rather than by any structural cost reduction, since R&D remained elevated relative to revenue across most periods. Operating leverage is therefore positive only in the sense that a high-revenue quarter temporarily offsets an otherwise fixed cost base. Investors should watch whether R&D intensity declines as revenue normalizes, as sustained losses at current spend levels would warrant further investigation.

Net Income Diverges Sharply From Operating Results

Based on the reported figures, XLO posted a net income of $10.4M in 2025Q4 despite an operating loss of -$11.8M, a gap of roughly $22M that the supplied data does not explain and that warrants further investigation.

A positive net result against a deeply negative operating line typically reflects non-operating items such as investment gains, financing-related adjustments, or tax effects, but the supplied data does not disclose their composition. EPS swings from -$1.54 to +$0.81 across adjacent quarters reinforce that reported earnings are heavily influenced by items outside core operations. Investors should treat reported EPS as a noisy indicator of underlying operating performance.

R&D Dominates the Cost Structure

According to the reported quarterly data, R&D expense ranged from $8.3M to $19.8M over the ten quarters, consistently exceeding SG&A and representing the largest operating cost line for XLO throughout the period.

R&D intensity relative to revenue remains very high, which is typical of clinical-stage biotechnology but leaves limited margin for error if collaboration income slows. SG&A has remained comparatively stable between roughly $5.8M and $8.5M, suggesting overhead discipline, though it does not offset the research burden. Stock-based compensation of $1.1M to $2.9M per quarter is modest relative to total operating expense and does not appear to be a principal driver of the loss profile.

Revenue Recognition Could Mask Underlying Weakness

The strongest challenge to XLO's recent improvement is that the 2026Q2 revenue spike of $18.7M may be non-recurring, and that gross profit of $18.7M against zero COGS could overstate the business's sustainable economics.

Collaboration revenue recognized in a single quarter can create the appearance of a turnaround that reverses when milestone payments conclude, as the 2025Q2 quarter with negative gross profit of -$7.2M illustrates. Peer comparisons show XLO's operating margin profile is weak relative to RCUS and TGTX, which have established revenue bases. Investors should assess whether quarterly volatility reflects structural strength or episodic recognition before extrapolating recent results.

XLO — Frequently Asked Questions

Quick answers to the most common questions about buying XLO stock.

What was Xilio Therapeutics, Inc.'s (XLO) revenue in 2025?

For fiscal year 2025, Xilio Therapeutics, Inc. (XLO) reported total revenue of $43.8M.

Is Xilio Therapeutics, Inc. (XLO) profitable?

Xilio Therapeutics, Inc. (XLO) reported a net loss of $35.0M for the fiscal year ending 2025.

What is Xilio Therapeutics, Inc.'s operating profit margin?

Xilio Therapeutics, Inc. (XLO) reported an operating income of $-42.0M, resulting in an operating profit margin of -95.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Xilio Therapeutics, Inc.'s gross profit and gross margin?

Xilio Therapeutics, Inc. (XLO) generated $42.2M in gross profit for the year, representing a gross profit margin of 96.5%. This demonstrates the company's core pricing power and production efficiency.